128 related articles for article (PubMed ID: 17966220)
1. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.
Pozlep B; Meleh M; Kobal B; Verdenik I; Osredkar J; Kralj LZ; Meden-Vrtovec H
Eur J Gynaecol Oncol; 2007; 28(5):394-9. PubMed ID: 17966220
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid: an ovarian cancer marker.
Sedláková I; Vávrová J; Tosner J; Hanousek L
Eur J Gynaecol Oncol; 2008; 29(5):511-4. PubMed ID: 19051824
[TBL] [Abstract][Full Text] [Related]
5. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer.
Meleh M; Pozlep B; Mlakar A; Meden-Vrtovec H; Zupancic-Kralj L
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):287-91. PubMed ID: 17766199
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis.
Cao L; Zhang Y; Fu Z; Dong L; Yang S; Meng W; Li Y; Zhang W; Zhang J; Zheng C; Zhu H; Fan L
J Obstet Gynaecol Res; 2015 Dec; 41(12):1951-8. PubMed ID: 26472266
[TBL] [Abstract][Full Text] [Related]
7. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors.
Tokumura A; Tominaga K; Yasuda K; Kanzaki H; Kogure K; Fukuzawa K
Cancer; 2002 Jan; 94(1):141-51. PubMed ID: 11815970
[TBL] [Abstract][Full Text] [Related]
8. [Lysophosphatidic acid in ovarian cancer patients].
Sedlákova I; Vávrová J; Tosner J; Hanousek L
Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.
Sedláková I; Vávrová J; Tošner J; Hanousek L
Tumour Biol; 2011 Apr; 32(2):311-6. PubMed ID: 21061112
[TBL] [Abstract][Full Text] [Related]
10. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
11. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Eur J Gynaecol Oncol; 1996; 17(1):29-35. PubMed ID: 8750512
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases.
Shen Z; Wu M; Elson P; Kennedy AW; Belinson J; Casey G; Xu Y
Gynecol Oncol; 2001 Oct; 83(1):25-30. PubMed ID: 11585410
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: a meta-analysis.
Lu Z; Chen Y; Hu Z; Hu C
Int J Gynecol Cancer; 2015 Jan; 25(1):18-23. PubMed ID: 25398018
[TBL] [Abstract][Full Text] [Related]
15. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract][Full Text] [Related]
16. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
[TBL] [Abstract][Full Text] [Related]
17. Detection of the Ovarian Cancer Biomarker Lysophosphatidic Acid in Serum.
De La Franier B; Thompson M
Biosensors (Basel); 2020 Feb; 10(2):. PubMed ID: 32075013
[TBL] [Abstract][Full Text] [Related]
18. Methods for quantifying lysophosphatidic acid in body fluids: a review.
Jesionowska A; Cecerska E; Dolegowska B
Anal Biochem; 2014 May; 453():38-43. PubMed ID: 24613261
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].
Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study.
Minis E; Holcomb K; Sisti G; Nasioudis D; Kanninen TT; Athanasiou A; Frey MK; Chapman-Davis E; Caputo TA; Witkin SS
Eur J Obstet Gynecol Reprod Biol X; 2019 Apr; 2():100012. PubMed ID: 31396597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]